CYTOTOXIC PROPERTIES OF TRITERPENE SAPONIN TAUROSID SX1 AND ITS EFFECT ON HUMAN IMMUNODEFICIENCY VIRUS AND INFLUENZA VIRUS INFECTION IN MICE

Cover Page

Cite item

Abstract

Triterpene saponin Taurosid Sx1 purified from leaves of the plant Crimean Ivy Hedera taurica Carr. (Araliaceae) was evaluated for its cytotoxic activity against lymphoblastoid cell lines MT-4, Jurkat-tat, U937, and human peripheral blood monocytes. The ability of saponin to influence HIV-1 replication was studied as well. In addition, the ability of Taurosid Sx1 to increase survival of mice infected with influenza virus А/WSN/1/33(H1N1) and its capacity for strengthening the immune responses in mice immunized with the influenza vaccine Grippol® have been studied. Taurosid Sx1 has been shown to inhibit MT-4 cell line at 25 μg ml-1 concentration, IC50 33,3 μmol l-1 (MTT assay). The saponin concentration of 5 μg ml-1 was non-toxic for all the cell lines studied and demonstrated a moderate inhibitory effect on HIV p24 production in Jurkat-tat cells. In the lower concentrations Taurosid Sx1 did not stimulate HIV p24 production. It was shown that oral administration of 200 μg Taurosid Sx1 to the influenza virus infected mice caused 1.5-fold increase in their survival. Taurosid Sx1 given orally amplified immunopotentiating ability of an intramusculary administered subunit influenza vaccine. Antibody production was significantly higher in animals fed Taurosid Sx1 after primary or secondary immunizatuion. In mice given 2 doses of vaccine, from 1 to 3 weeks apart, feeding 200 μg saponin resulted in 2 to 10-fold enhancement in production of anti-H1, anti-H3, and anti-inluenza type B hemagglutinin antibodies. Thus, Taurosid Sx1 can be considered as low-toxic promising immunopotentiating agent uncapable of enhancing HIV-1 replication.

About the authors

Yu. L. Krivorutchenko

Medical Academy named after S.I. Georgievsky, Federal State Autonomous Educational Institution of Higher Education «V. I. Vernadsky Crimean Federal University»

Author for correspondence.
Email: noemail@neicon.ru
Russian Federation

D. N. Nosik

D.I. Ivanovsky Institute of Virology, «National Research Center for Epidemiology and Microbiology named after the honorary academician N.F. Gamaleya»

Email: noemail@neicon.ru
Russian Federation

V. Yu. Maligina

Medical Academy named after S.I. Georgievsky, Federal State Autonomous Educational Institution of Higher Education «V. I. Vernadsky Crimean Federal University»

Email: noemail@neicon.ru
Russian Federation

O. A. Lobach

D.I. Ivanovsky Institute of Virology, «National Research Center for Epidemiology and Microbiology named after the honorary academician N.F. Gamaleya»

Email: victoriola@yandex.ru
Russian Federation

I. B. Andronovskaja

Medical Academy named after S.I. Georgievsky, Federal State Autonomous Educational Institution of Higher Education «V. I. Vernadsky Crimean Federal University»

Email: noemail@neicon.ru
Russian Federation

M. A. Kirsanova

Medical Academy named after S.I. Georgievsky, Federal State Autonomous Educational Institution of Higher Education «V. I. Vernadsky Crimean Federal University»

Email: noemail@neicon.ru
Russian Federation

V. I. Grishkovets

Medical Academy named after S.I. Georgievsky, Federal State Autonomous Educational Institution of Higher Education «V. I. Vernadsky Crimean Federal University»

Email: noemail@neicon.ru
Russian Federation

References

  1. Pingen M., Nijhuis M., de Bruijn J.A., Boucher C.A., Wensing A.M. Evolutionary pathways of transmitted drug-resistant HIV-1. J. Antimicrob. Chemother. 2011; 66(7): 1467-80.
  2. Hayden F.G., de Jong M.D. Emerging influenza antiviral resistance threats. J. Infect. Dis. 2011; 203(1): 6-10.
  3. Cohen Y.Z., Dolin R. Novel HIV vaccine strategies: overview and perspective. Ther. Adv. Vaccines. 2013; 1(3): 99-112.
  4. Di Pasquale A., Preiss S., Da Silva F.T., Garcon N. Vaccine adjuvants: from 1920 to 2015 and beyond. Vaccines (Basel). 2015; 3(2): 320-43.
  5. Салтыкова Т.С., Романенко В.В., Минаев О.В. Эпидемиологическая и экономическая эффективность иммунизации взрослого работоспособного населения вакциной «Гриппол® плюс». Эпидемиология и инфекционные болезни. Актуальные вопросы. 2015; (5): 65-71
  6. Mushi N.V., Mbwambo Z.H., Innocent E., Tewtrakul S. Antibacterial, anti-HIV-1 protease and cytotoxic activities of aqueous ethanolic extracts from Combretum adenogonium Steud. Ex A. Rich (Combretaceae). BMC Complement. Altern. Med. 2012; 12(1): 163.
  7. Podolak I., Galanty A., Sobolewska D. Saponins as cytotoxic agents: a review. Phytochem. Rev. 2010; 9(3): 425-74.
  8. Huang L., Chen C.H. Molecular targets of anti-HIV-1 triterpenes. Curr. Drug Targets Infect. Disord. 2002; 2(1): 33-6.
  9. Lee S., Nguyen M.T. Recent advances of vaccine adjuvants for infectious diseases. Immune Netw. 2015; 15(2): 51-7.
  10. Krivorutchenko Y.L., Andronovskaja I.B., Hinkula J., Krivoshein Y.S., Ljungdahl-Stahle E., Pertel S.S., et al. Study of the adjuvant activity of new MDP derivatives and purified saponins and their influence on HIV-1 replication in vitro. Vaccine. 1997; 15(12-13): 1479-86.
  11. Криворутченко Ю.Л., Кирсанова М.А., Андроновская И.Б. Антифунгальное действие тритерпенового сапонина таурозида Sx1 из Hedera taurica Carr. в отношении клинических изолятов Candida spp. Проблемы медицинской микологии. 2015; 17(3): 42-5.
  12. Гришковец В.И., Толкачёва Н.В., Шашкова А.С., Чирва В.Я. Тритерпеновые гликозиды из Hedera Taurica. 10. Структура соединений F4, I и J из листьев крымского плюща. Химия природных соединений. 1992; (6): 683-6.
  13. Малыгина В.Ю., Андроновская И.Б., Криворутченко Ю.Л., Гришковец В.И. Зависимость протективного действия таурозида Sx1 от доз, способа и схем введения сапонина при экспериментальном гриппе у мышей. Крымский журнал экспериментальной и клинической медицины. 2012; 2(1-2): 98-102.
  14. Niks M., Otto M. Towards an optimized MTT assay. J. Immunol. Methods. 1990; 130(1): 149-51.
  15. Melek F.R., Miyase T., Ghaly N.S., Nabil M. Triterpenoid saponins with N-acetyl sugar from bark of Albizia procera. Phytochemistry. 2007; 68(9): 1261-6.
  16. Galanty A., Michalik M., Sedek L., Podolak I. The influence of LTS-4, a saponoside from Lysimachia thyrsiflora L., on human skin fibroblasts and human melanoma cells. Cell. Mol. Biol. Lett. 2008; 13(4): 585-98.
  17. Криворутченко Ю.Л., Андроновская И.Б., Чирва В.Я., Пертель С.С., Гришковец В.И., Земляков А.Е. и др. Влияние сапонинов из Hedera taurica Carr. и модифицированных мурамилпептидов на репродукцию вируса иммунодефицита человека in vitro. Вопросы вирусологии. 1997; 42(1): 34-6
  18. Chavali S.R., Barton L.D., Campbell J.B. Immunopotentiation by orally-administered Quillaja saponins: effects in mice vaccinated intraperitoneally against rabies. J. Clin. Exp. Immunol. 1988; 74(3): 339-43

Copyright (c) 2018 Krivorutchenko Y.L., Nosik D.N., Maligina V.Y., Lobach O.A., Andronovskaja I.B., Kirsanova M.A., Grishkovets V.I.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС77-77676 от 29.01.2020.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies